Corix Bioscience, Inc.
CXBS
$0.00
$0.000.00%
OTC PK
| 09/30/2017 | 06/30/2017 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -57.20% | 83.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -56.90% | 83.33% | |||
| Operating Income | 56.90% | -83.33% | |||
| Income Before Tax | 64.84% | -91.77% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 64.84% | -91.77% | |||
| Earnings from Discontinued Operations | -283.67% | -65.77% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -45.48% | -82.70% | |||
| EBIT | 56.90% | -83.33% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -38.43% | -34.06% | |||
| Normalized Basic EPS | 28.38% | -34.71% | |||
| EPS Diluted | -38.43% | -34.06% | |||
| Normalized Diluted EPS | 28.38% | -34.71% | |||
| Average Basic Shares Outstanding | 5.16% | 36.16% | |||
| Average Diluted Shares Outstanding | 5.16% | 36.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||